Epithalon vs BPC-157
Both compounds are synthetic peptides with substantial preclinical literatures, but the published research examines entirely different biological domains. Epithalon (AEDG tetrapeptide) has been investigated for telomerase regulation and aging-related endpoints. BPC-157 has been investigated for tissue-repair and vascular-pathway activity. This page summarises how the published research separates them.
Side-by-side comparison
| Property | Compound A | Compound B |
|---|---|---|
| Structural class | Tetrapeptide (Ala-Glu-Asp-Gly); synthetic analogue of the pineal gland peptide epithalamin | 15-residue pentadecapeptide; partial sequence of a protein from gastric juice |
| Approximate molecular weight | 390.3 g/mol | 1419.6 g/mol |
| Best-studied mechanism | Telomerase upregulation; telomere-length maintenance; melatonin-synthesis modulation | VEGFR2 pathway engagement; Akt/eNOS signalling; growth-factor expression |
| Primary research domain | Aging biology, telomere research, carcinogenesis, oocyte aging | Tissue repair: gastric mucosa, tendon-ligament-bone, vascular endothelium |
| Common research routes | Intraperitoneal, intranasal in rodent and Drosophila studies | Intraperitoneal, oral, subcutaneous in rodent studies |
| Reconstitution practice | Bacteriostatic water; lyophilised vial format | Bacteriostatic water; lyophilised vial format |
| Ronin catalog vial size | 10 mg lyophilised | 10 mg lyophilised |
How they differ in mechanism
Epithalon (AEDG peptide) has been studied for telomerase-upregulation effects. The published literature includes telomere-length maintenance in human cell lines (Al-Dulaimi et al., 2025), lifespan extension in Drosophila melanogaster (Khavinson et al., 2000), carcinogenesis inhibition in rodent models (Anisimov et al., 2002; Kossoy et al., 2006), and neurogenesis-related gene-expression stimulation (Khavinson et al., 2020). The mechanistic frame centres on aging biology and telomere maintenance.
BPC-157 has been investigated through the VEGFR2 pathway with downstream Akt and eNOS signalling. Published endpoints include gastric-mucosa repair, tendon-ligament-bone interface recovery, peripheral-nerve models, and microvascular-density modulation. The compound’s gastric stability and multi-route administration are distinctive features of the published literature.
The two compounds address entirely different biological questions. Epithalon operates in the aging-biology and telomere-maintenance domain. BPC-157 operates in the tissue-repair and vascular-signalling domain. They share the broad ‘research peptide’ category but have no mechanistic intersection.
How research has examined each
The epithalon literature spans work by Khavinson and colleagues on pineal-peptide biology, with studies on telomerase, lifespan, carcinogenesis inhibition, melatonin synthesis, neuronal-activity modulation, oocyte aging, and diabetic-retinopathy wound healing. The compound is positioned in the gerontology and aging-biology research space.
The BPC-157 literature centres on gastric-mucosa repair, tendon-ligament-bone models, peripheral-nerve studies, and vascular-endothelium research. The mechanistic consistency around VEGFR2-Akt-eNOS spans over two decades of predominantly Croatian research-group publications.
The two literatures share no primary citations, model systems, or research communities. Epithalon is read by gerontologists and telomere biologists. BPC-157 is read by gastroenterologists, orthopaedic researchers, and vascular biologists.
Stacking considerations in research contexts
Combined administration of epithalon and BPC-157 is not described in published research. The mechanisms (telomerase regulation versus VEGFR2-mediated tissue repair) are entirely unrelated. Both compounds are sold as separate 10 mg lyophilised vials in the Ronin catalog.
Sourcing both at Ronin
Both compounds ship as 10 mg lyophilised peptide in glass vials with certificate-of-analysis documentation. The Epithalon vial page and the BPC-157 vial page carry per-compound spec sheets. Both are research-grade reagents.
Frequently asked research questions
Are epithalon and BPC-157 related?
No. Epithalon is a tetrapeptide from pineal-gland biology. BPC-157 is a pentadecapeptide from gastric-juice research. Different origins, sequences, and mechanisms.
Do they target the same biological domain?
No. Epithalon is studied for aging, telomerase, and telomere endpoints. BPC-157 is studied for tissue repair, vascular signalling, and gastric protection.
Are they stacked in research?
Not in published research. The domains are non-overlapping.
Do they share storage practice?
Yes. Both are lyophilised peptides, reconstituted in bacteriostatic water, stored at 2-8 degrees Celsius.
Are either approved for human use?
Neither is approved by the FDA or Health Canada. Both are research-grade reagents.
References
- Khavinson VK et al. Effect of epitalon on the lifespan increase in Drosophila melanogaster. Mechanisms of Ageing and Development, 2000. [PMID 11087911]
- Anisimov VN et al. Inhibitory effect of peptide Epitalon on colon carcinogenesis induced by 1,2-dimethylhydrazine in rats. Cancer Letters, 2002. [PMID 12049808]
- Khavinson V et al. AEDG Peptide (Epitalon) Stimulates Gene Expression and Protein Synthesis during Neurogenesis. Molecules, 2020. [PMID 32019204]
- Sikiric P et al. The Stable Gastric Pentadecapeptide BPC 157 Pleiotropic Beneficial Activity. Pharmaceuticals, 2024. [PMID 38675421]
- Araj SK et al. Overview of Epitalon-Highly Bioactive Pineal Tetrapeptide with Promising Properties. International Journal of Molecular Sciences, 2025. [PMID 40141333]
- Al-Dulaimi S et al. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology, 2025. [PMID 40908429]
Comparison pages describe research-context use of the compared compounds. They do not constitute medical, veterinary, or clinical advice. Every compound in the Ronin catalog is sold strictly for laboratory and research use only.